南新制药(688189) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥134,213,325.60, a decrease of 50.03% compared to the same period last year[5] - The net profit attributable to shareholders was ¥7,061,002.04, down 67.24% year-on-year[5] - The basic earnings per share for the quarter was ¥0.0504, reflecting a decline of 67.24% compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,524,246.53, a decrease of 62.84% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2021 was CNY 565,410,643.65, a decrease of 33.4% compared to CNY 849,142,132.03 in the same period of 2020[20] - Net profit for the first three quarters of 2021 was CNY 47,827,466.53, a decline of 36.0% from CNY 74,769,473.79 in 2020[21] - Basic earnings per share for the first three quarters of 2021 were CNY 0.3511, compared to CNY 0.5538 in the same period of 2020[22] Research and Development - Research and development expenses totaled ¥17,673,886.49, representing 13.17% of operating revenue, an increase of 0.98 percentage points year-on-year[6] - Research and development projects are progressing steadily, with no significant changes in the current reporting period compared to the previous half-year[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,311,572,629.25, an increase of 9.92% from the end of the previous year[6] - Current assets totaled CNY 1,940,985,153.41, up from CNY 1,729,597,539.22, indicating an increase of about 12.14%[15] - Total liabilities as of the end of the reporting period were CNY 679,579,857.78, an increase of 42.1% from CNY 478,069,049.51 in the previous year[20] - Non-current liabilities totaled CNY 87,910,993.02, a slight increase from CNY 85,269,728.61 in the previous year[20] - The company has a total of 7,310 common shareholders as of the reporting period[13] - The largest shareholder, Hunan Xiangtou Holding Group Co., Ltd., holds 28.57% of the shares, totaling 40,000,000 shares[13] Cash Flow - The company reported a cash flow from operating activities of -¥193,890,789.30 for the year-to-date[5] - Net cash flow from operating activities was -$193.89 million, compared to -$176.91 million in the previous period, indicating a decline in operational cash generation[25] - Cash received from sales of goods and services in the first three quarters of 2021 was CNY 423,825,017.52, a decrease of 32.1% from CNY 624,977,283.91 in 2020[24] - Cash paid for operating activities was $643.71 million, down from $842.44 million, suggesting improved cost management[25] - Cash inflow from financing activities amounted to $435 million, compared to $1.35 billion in the previous period, reflecting a decrease in financing receipts[26] - Net cash flow from financing activities was $164.63 million, down from $1.10 billion in the prior period, indicating reduced financing activity[26] Inventory and Receivables - Accounts receivable increased to CNY 855,073,412.28 from CNY 702,977,210.62, representing a growth of around 21.63%[15] - Inventory levels rose to CNY 96,503,106.62 from CNY 48,647,769.15, reflecting an increase of about 98.24%[16] - The company reported a significant increase in accounts payable, which rose to CNY 37,906,234.06 from CNY 20,207,678.52, representing an increase of approximately 87.51%[16] Market Impact - The decline in revenue and profit was primarily attributed to the ongoing impact of the pandemic on market sales and logistics[11]